Maximum quantity allowed is 999
请选择数量
CAS RN: 212142-18-2 | 产品编码: V0198
| 产品编码 | V0198 |
| 纯度/分析方法 | >98.0%(T)(HPLC) |
| 分子式/分子量 | C__2__0H__1__5ClN__4·C__4H__6O__4 = 464.91 |
| 外观与形状（20°C） | 固体 |
| 储存温度 | 冷冻 (-20°C) |
| 储存在惰性气体下 | 存放于惰性气体之中 |
| 应避免的情况 | 空气,加热 |
| CAS RN | 212142-18-2 |
| Reaxys-RN | 14123653 |
技术规格
| Appearance | White to Light yellow to Light orange powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Nonaqueous Titration) | min. 98.0 % |
| NMR | confirm to structure |
物性（参考值）
GHS
相关法规
运输信息
| HS编码* | 2933.39-000 |
应用
Vatalanib Succinate: A Specific Inhibitor of VEGF Receptor Tyrosine Kinases
Vascular endothelial growth factor (VEGF) is one of the major factors involved in tumor angiogenesis and has become an important target for cancer therapy. Vatalanib succinate (PTK787 /ZK 222584) is a specific inhibitor of all three VEGF receptor (VEGF-R1, VEGF-R2 and VEGF-R3) tyrosine kinases, which shows antitumor and anti-angiogenic activity in cancer cells. (The product is for research use only.)
References
- PTK787 /ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
- Effects of PTK787 /ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
- PTK787 /ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging
- Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787 /ZK 222584 (a review)
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。